Lundbeck Recalls Injectable Drug After Finding Particulates

Lundbeck has voluntarily recalled two lots of NeoProfen injection that failed to meet a visible particulate quality requirement.

The company is investigating the cause of the particulates, Lundbeck spokesman Matt Flesch said. The company discovered the issue during a recent inspection of the lots.

Lundbeck has not received adverse event reports or product complaints attributable to visible particulates from any lot of the drug, the company said. The two lots affected are the only ones available to prescribers, so the recall was expected to result in a temporary product shortage.
Drug GMP Report